

Clinical trials of dabigatran 110mg

TrialResults-center www.trialresultscenter.org

1 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
dabigatran 110mg vs warfarin standard dose			
RE-LY (110mg) , 2009 [NCT00262600] n=6015/6022 follow-up: 2 y (median)	dabigatran 110 mg twice a day versus warfarin adjusted dose to a 2-3 INR	Patients With Non-Valvular Atrial Fibrillation	Parallel groups open (blind assessment) 44 countries

More details and results :

- antithrombotics for atrial fibrillation in primary prevention of thromboembolic events at <http://www.trialresultscenter.org/go-Q57>
- direct antithrombins for atrial fibrillation in all type of patients at <http://www.trialresultscenter.org/go-Q368>
- direct oral anticoagulant (DAO) for atrial fibrillation in all type of patients at <http://www.trialresultscenter.org/go-Q391>

References

RE-LY (110mg), 2009:

Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S Am Heart J 2009;157:805-10, 810.e1-2 [[19376304](#)]
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009 Aug 30;: [[19717844](#)]
[10.1056/NEJM0a0905561](#)

Entry terms: dabigatran, Pradaxa, Pradax